Hanneke Wilmink

List of Publications by Year
in descending order

Source: //exaly.com/author-pdf/806926/publications.pdf

Version: 2024-02-01

77 papers	3,871 citations	184648 27 h-index	129810 58 g-index
122 all docs	122 docs citations	122 times ranked	6679 citing authors

#	Article	IF	Citations
1	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	5.4	730
2	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	5.4	353
3	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 839-847.	10.7	330
4	Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene, 2018, 37, 1949-1960.	5.9	178
5	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.9	130
6	Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 4352-4360.	1.9	125
7	Neoadjuvant therapy or upfront surgery for resectableÂand borderline resectable pancreatic cancer: AÂmeta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 160, 140-149.	2.9	109
8	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncology, 2020, 6, 1733.	7.3	93
9	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research, 2018, 24, 1705-1715.	7.2	86
10	Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta OncolÃ³gica, 2019, 58, 1048-1055.	1.8	79
11	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta OncolÃ³gica, 2018, 57, 1655-1662.	1.8	77
12	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 146, 1445-1456.	5.4	73
13	Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. Hpb, 2018, 20, 605-611.	0.3	72
14	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Hpb, 2020, 22, 233-240.	0.3	72
15	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Annals of Surgical Oncology, 2017, 24, 2734-2743.	1.9	70
16	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients withIDH1-mutated orIDH2-mutated solid tumours. BMJ Open, 2017, 7, e014961.	2.1	70
17	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	3.8	65
18	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	10.7	55

#	Article	IF	Citations
19	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Annals of Surgery, 2020, 271, e102-e104.	4.4	48
20	Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients. PLoS ONE, 2018, 13, e0194590.	2.5	47
21	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. Radiotherapy and Oncology, 2015, 116, 94-99.	0.6	45
22	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 588.	3.8	44
23	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Annals of Surgical Oncology, 2020, 27, 2516-2524.	1.9	43
24	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. International Journal of Hyperthermia, 2018, 34, 969-979.	2.5	42
25	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Modern Pathology, 2021, 34, 4-12.	5.6	42
26	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. British Journal of Cancer, 2020, 122, 634-639.	6.5	41
27	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. European Journal of Cancer, 2019, 106, 99-105.	2.9	34
28	Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body orÂTail on Surgical and Oncological Outcome: A Propensity-ScoreÂMatched Multicenter Study. Annals of Surgical Oncology, 2020, 27, 1986-1996.	1.9	31
29	Highâ€grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSFâ€1. EMBO Reports, 2020, 21, e48780.	4.5	29
30	IDH1â€mutant cancer cells are sensitive to cisplatin and an IDH1â€mutant inhibitor counteracts this sensitivity. FASEB Journal, 2018, 32, 6344-6352.	0.4	28
31	Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study. International Journal of Radiation Oncology Biology Physics, 2014, 90, 190-196.	0.8	24
32	Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol. BMJ Open, 2017, 7, e015810.	2.1	24
33	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A populationâ€based study. Cancer Medicine, 2018, 7, 4943-4951.	2.9	23
34	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. European Journal of Surgical Oncology, 2021, 47, 2525-2532.	1.0	23
35	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 8297-8308.	1.9	22
36	Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies. Hpb, 2019, 21, 865-875.	0.3	21

#	Article	IF	Citations
37	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1052-1062.	0.8	20
38	Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment. Cancers, 2021, 13, 5089.	3.8	20
39	Lost in translation: confusion on resection and dissection planes hampers the interpretation of pathology reports for perihilar cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 435-443.	2.9	19
40	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. European Journal of Surgical Oncology, 2021, 47, 699-707.	1.0	19
41	Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma. Magnetic Resonance Imaging, 2018, 50, 1-9.	1.9	18
42	Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. Hpb, 2019, 21, 1385-1392.	0.3	16
43	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. Cancer Medicine, 2020, 9, 9385-9395.	2.9	16
44	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. Investigational New Drugs, 2018, 36, 53-61.	2.7	15
45	Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Journal of Vascular and Interventional Radiology, 2020, 31, 1600-1608.	0.5	15
46	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer, 2019, 19, 1133.	2.6	14
47	Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. Hpb, 2020, 22, 405-414.	0.3	14
48	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.8	14
49	The association between wearable activity monitor metrics and performance status in oncology: a systematic review. Supportive Care in Cancer, 2021, 29, 7085-7099.	2.3	13
50	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	7.2	12
51	Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 141, 82-94.	4.5	12
52	Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. Hpb, 2022, 24, 1433-1442.	0.3	12
53	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Frontiers in Oncology, 2022, 12, 839779.	2.9	12
54	Realâ€world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. International Journal of Cancer, 2022, 150, 1654-1663.	5.4	11

#	Article	IF	Citations
55	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. International Journal of Molecular Sciences, 2021, 22, 10902.	4.2	10
56	Age and prognosis in patients with pancreatic cancer: a population-based study. Acta OncolÃ³gica, 2022, 61, 286-293.	1.8	10
57	The Dutch Pancreas Biobank Within the Parelsnoer Institute. Pancreas, 2018, 47, 495-501.	1.1	9
58	Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial. European Journal of Cancer, 2020, 125, 94-103.	2.9	9
59	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Pancreatology, 2020, 20, 1723-1731.	1.8	9
60	Treatment and Survival of Elderly Patients with Stage Iâ€“II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Annals of Surgical Oncology, 2020, 27, 5337-5346.	1.9	9
61	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta OncolÃ³gica, 2020, 59, 705-712.	1.8	9
62	Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Biomarkers, 2021, 26, 325-334.	1.7	9
63	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers, 2021, 13, 4869.	3.8	9
64	RE: Colorectal Cancer Incidence Patterns in the United States, 1974â€“2013. Journal of the National Cancer Institute, 2017, 109, .	6.3	8
65	CirculatingTP53mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110337.	3.4	8
66	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. Drug Delivery, 2017, 24, 1801-1810.	5.8	7
67	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. European Journal of Surgical Oncology, 2021, 47, 1742-1749.	1.0	5
68	The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. Hpb, 2022, 24, 443-451.	0.3	5
69	Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma. World Journal of Gastrointestinal Oncology, 2020, 12, 347-357.	2.0	5
70	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. Frontiers in Oncology, 2021, 11, 744161.	2.9	5
71	The fear of cancer recurrence and progression in patients with pancreatic cancer. Supportive Care in Cancer, 2022, 30, 4879-4887.	2.3	5
72	Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Hpb, 2023, 25, 1195-1202.	0.3	5

#	Article	IF	Citations
73	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. Hpb, 2021, 23, 1886-1896.	0.3	3
74	Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta OncolÃ³gica, 2022, 61, 591-596.	1.8	2
75	The effect of metformin on bladder cancer incidence and outcomes â€“a systematic review and meta-analysis. Bladder Cancer, 2022, , 1-18.	0.4	1
76	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. Journal of Clinical Oncology, 0, , .	5.4	1
77	The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy. Cancer Immunology Research, 2024, 12, 759-778.	3.3	1